163 related articles for article (PubMed ID: 32314029)
1. The influence of PD-L1 genetic variation on the prognosis of R0 resection colorectal cancer patients received capecitabine-based adjuvant chemotherapy: a long-term follow-up, real-world retrospective study.
Su J; Dai B; Yuan W; Wang G; Zhang Z; Li Z; Liu J; Song J
Cancer Chemother Pharmacol; 2020 May; 85(5):969-978. PubMed ID: 32314029
[TBL] [Abstract][Full Text] [Related]
2. [Influence of genetic variation of programmed death-ligand 1 (PD-L1) on the prognosis of patients with non-small cell lung cancer who received platinum-based adjuvant chemotherapy].
Zhang GW; Cheng RR; Zhang FR; Li P; Chu HY; Song XJ; Zhang GJ
Zhonghua Yi Xue Za Zhi; 2020 Sep; 100(34):2682-2688. PubMed ID: 32921017
[No Abstract] [Full Text] [Related]
3. [The influence of Thymidine Phosphorylase genetic variation on clinical outcomes and safety of colorectal cancer patients received adjuvant chemotherapy after R0 resection].
Du YB; Zhang TF; Cui K; Jin SL; Xi Y; Ma W
Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(32):2569-2573. PubMed ID: 30220141
[No Abstract] [Full Text] [Related]
4. [The influence of XRCC1 gene polymorphism on the prognosis and safety of stage Ⅲ patients with colorectal cancer who received oxaliplatin based adjuvant chemotherapy].
Li RX; Shang JH; Sun JF
Zhonghua Yi Xue Za Zhi; 2021 Mar; 101(11):759-765. PubMed ID: 33765714
[No Abstract] [Full Text] [Related]
5. Rs11479 in
Jia X; Zhang T; Sun J; Lin H; Bai T; Qiao Y; Li Y; Li G; Li G; Peng X; Zhang A
Pharmgenomics Pers Med; 2023; 16():277-289. PubMed ID: 37025557
[TBL] [Abstract][Full Text] [Related]
6. [Clinical outcomes of gastric cancer patients received capecitabine based adjuvant chemotherapy and the corresponding pharmacogenomics analysis].
Chen WC; Wu G; Zhang W; Zhu YZ; Zhou Y; Zhang H; Xia XB; Sun PC
Zhonghua Yi Xue Za Zhi; 2018 Nov; 98(42):3420-3425. PubMed ID: 30440137
[No Abstract] [Full Text] [Related]
7. [Influence of apatinib and VEGFR2-906T>C polymorphism on clinical outcomes of advanced non-small cell lung cancer patients].
Zhao RH; Zhou YN; Li H; Li R; Zhang WJ; Zong H
Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(2):105-110. PubMed ID: 30669747
[No Abstract] [Full Text] [Related]
8. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
9. [The impact of genetic variation of KDR on clinical outcomes of advanced colorectal cancer patients treated by first line bevacizumab based regimens].
Wang HX; Mei X; Gong TX; Han N; Liu P; Wang J; Zhang ZM
Zhonghua Yi Xue Za Zhi; 2018 Sep; 98(34):2737-2742. PubMed ID: 30220171
[No Abstract] [Full Text] [Related]
10. Influence of VEGFR2 gene polymorphism on the clinical outcomes of apatinib for patients with chemotherapy-refractory extensive-stage SCLC: a real-world retrospective study.
Geng N; Ding CM; Liu ZK; Song S; Hu WX
Int J Clin Oncol; 2021 Apr; 26(4):670-683. PubMed ID: 33392882
[TBL] [Abstract][Full Text] [Related]
11. Influence of KDR Genetic Variation on the Efficacy and Safety of Patients with Chemotherapy Refractory Metastatic CRC Who Received Apatinib Treatment.
Bai M; Li ZG; Ba Y
Int J Gen Med; 2021; 14():1041-1055. PubMed ID: 33790633
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.
Hamaguchi T; Shimada Y; Mizusawa J; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Takiguchi N; Yatsuoka T; Takii Y; Ojima H; Masuko H; Kubo Y; Mishima H; Yamaguchi T; Bando H; Sato T; Kato T; Nakamura K; Fukuda H; Moriya Y
Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):47-56. PubMed ID: 29079411
[TBL] [Abstract][Full Text] [Related]
13. Influence of
Zhao M; Zhang J; Chen S; Wang Y; Tian Q
Cancer Manag Res; 2020; 12():6755-6766. PubMed ID: 32801904
[TBL] [Abstract][Full Text] [Related]
14. Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil.
Hitre E; Budai B; Adleff V; Czeglédi F; Horváth Z; Gyergyay F; Lövey J; Kovács T; Orosz Z; Láng I; Kásler M; Kralovánszky J
Pharmacogenet Genomics; 2005 Oct; 15(10):723-30. PubMed ID: 16141798
[TBL] [Abstract][Full Text] [Related]
15. Association of PD-1 and PDL-1 gene polymorphisms with colorectal cancer risk and prognosis.
Cevik M; Namal E; Iner-Koksal U; Dinc-Sener N; Karaalp A; Ciftci C; Susleyici B
Mol Biol Rep; 2022 Mar; 49(3):1827-1836. PubMed ID: 35076848
[TBL] [Abstract][Full Text] [Related]
16. Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study.
Choi YY; Kim H; Shin SJ; Kim HY; Lee J; Yang HK; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Choi SH; Hong S; Kim JW; Hyung WJ; Noh SH; Cheong JH
Ann Surg; 2019 Aug; 270(2):309-316. PubMed ID: 29727332
[TBL] [Abstract][Full Text] [Related]
17. Impact of sidedness of colorectal cancer on tumor immunity.
Takasu C; Nishi M; Yoshikawa K; Tokunaga T; Kashihara H; Yoshimoto T; Shimada M
PLoS One; 2020; 15(10):e0240408. PubMed ID: 33045001
[TBL] [Abstract][Full Text] [Related]
18. Polymorphism of the programmed death-ligand 1 gene is associated with its protein expression and prognosis in gastric cancer.
Wu Y; Zhao T; Jia Z; Cao D; Cao X; Pan Y; Zhao D; Zhang B; Jiang J
J Gastroenterol Hepatol; 2019 Jul; 34(7):1201-1207. PubMed ID: 30353572
[TBL] [Abstract][Full Text] [Related]
19. [Influence of polymorphisms of VEGFR2 on clinical outcomes and safety of advanced non-small-cell lung cancer treated by first line Bevacizumab plus chemotherapy regimens].
Fan HJ; Yuan J; Wu JJ; Jia YX; Ma YH; Li XY
Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(2):99-104. PubMed ID: 30669746
[No Abstract] [Full Text] [Related]
20. The association of polymorphisms in folate-metabolizing genes with response to adjuvant chemotherapy of colorectal cancer.
Yousef AM; Zawiah M; Al-Yacoub S; Kadi T; Tantawi DA; Al-Ramadhani H
Cancer Chemother Pharmacol; 2018 Aug; 82(2):237-243. PubMed ID: 29845393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
